公开(公告)号：EP3199952A1

公开(公告)日：2017-08-02

申请号：EP15843728.5

申请日：2015-09-24

申请人： Public University Corporation Nara Medical University ,  Chugai Seiyaku Kabushiki Kaisha

发明人： NOGAMI, Keiji ,  SHIMA, Midori ,  SOEDA, Tetsuhiro ,  KITAZAWA, Takehisa

IPC分类号： G01N33/86 ,  C07K16/36 ,  G01N33/53

CPC分类号： G01N33/86 ,  C07K16/36 ,  C07K2317/31 ,  G01N2333/755 ,  G01N2333/96444 ,  G01N2333/9645 ,  G01N2800/224 ,  G01N2800/52 ,  G01N2800/56

摘要： The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.

摘要翻译： 本发明人制备了中和具有功能性取代FVIII活性的双特异性抗体的活性的物质，并且进行了测量即使在该双特异性抗体存在下也可以确保准确性的FVIII反应性的方法的构建。 结果，本发明人发现，在基于APTT的一步凝固测定中，可以精确评估血友病A患者血浆中的FVIII活性，并且在基于APTT的Bethesda测定中，可以准确评估血浆中的FVIII抑制剂滴度 可以准确地评估携带FVIII抑制剂的血友病患者A.

公开(公告)号：EP2902787B1

公开(公告)日：2018-03-28

申请号：EP13842222.5

申请日：2013-09-26

申请人： Chugai Seiyaku Kabushiki Kaisha ,  Public University Corporation Nara Medical University

发明人： SOEDA, Tetsuhiro ,  KITAZAWA, Takehisa ,  SHIMA, Midori

IPC分类号： C12Q1/56 ,  G01N33/86 ,  C12N9/64

CPC分类号： C12Q1/56 ,  C12N9/6443 ,  G01N33/86 ,  G01N2333/755 ,  G01N2333/96452 ,  G01N2800/224

摘要： Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.

公开(公告)号：EP3690050A1

公开(公告)日：2020-08-05

申请号：EP18860741.0

申请日：2018-09-27

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： TERANISHI, Yuri ,  KATO, Kazuki ,  KOGA, Hikaru ,  IGAWA, Tomoyuki ,  YAMAGUCHI, Kazuki ,  SOEDA, Tetsuhiro

IPC分类号： C12N15/13 ,  A61K39/395 ,  A61P7/04 ,  C07K16/36 ,  C07K16/46 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

摘要： Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.

公开(公告)号：EP3318633A1

公开(公告)日：2018-05-09

申请号：EP17200495.4

申请日：2011-11-17

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： IGAWA, Tomoyuki ,  SAMPEI, Zenjiro ,  KOJIMA, Tetsuo ,  SOEDA, Tetsuhiro ,  MUTO, Atsushi ,  KITAZAWA, Takehisa ,  NISHIDA, Yukiko ,  IMAI, Chifumi ,  SUZUKI, Tsukasa ,  YOSHIHASHI, Kazutaka

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61P7/04 ,  C07K16/36 ,  C12N5/10 ,  C12P21/02

CPC分类号： C07K16/40 ,  C07K16/36 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/94

摘要： Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.

摘要翻译： 与血液凝固因子IX /激活的凝血因子IX和血液凝固因子X特异性结合并且在功能上取代凝血因子VIII的辅因子功能的各种双特异性抗体，即通过以下方式促进血液凝固因子X活化的功能： 产生活化的凝血因子IX。 从这些抗体中成功发现了功能性取代凝血因子VIII的多特异性抗原结合分子。

公开(公告)号：EP3047857A1

公开(公告)日：2016-07-27

申请号：EP14845545.4

申请日：2014-09-19

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： KITAZAWA, Takehisa ,  NAKANE, Aya ,  YOSHIHASHI, Kazutaka ,  SOEDA, Tetsuhiro ,  MUTO, Atsushi

IPC分类号： A61K39/395 ,  A61K45/00 ,  A61P7/04 ,  C07K16/18

CPC分类号： C07K16/40 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/76 ,  A61K2300/00

摘要： The present inventors have completed the present invention by finding that an excellent anticoagulation inhibitory effect is obtained by the administration of an agent inhibiting the activation of protein C.

摘要翻译： 本发明人通过发现通过施用抑制蛋白质C的活化的试剂获得优异的抗凝抑制效果，完成了本发明。

公开(公告)号：EP4155405A1

公开(公告)日：2023-03-29

申请号：EP21809537.0

申请日：2021-05-21

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： SOEDA, Tetsuhiro ,  HADANO, Jinki

IPC分类号： C12N15/13 ,  C07K16/40 ,  C07K16/42 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/63 ,  C12P21/08 ,  G01N33/53 ,  G01N33/86

摘要： Production was attempted for antibodies that neutralize the activity of a bispecific antibody having F.VIII function-substituting activity, for use in a method for measuring the reactivity of F.VIII in the presence of a bispecific antibody having F.VIII function-substituting activity. As a result, it was discovered that by using the produced antibodies, F.VIII activity in the plasma of a hemophilia A patient can be evaluated accurately by performing APTT-based one-stage clotting assay on a wide range of bispecific antibodies having F.VIII function-substituting activity. It was also discovered that F.VIII inhibitor titer in the plasma of a hemophilia A patient carrying F.VIII inhibitor can be evaluated accurately by APTT-based Bethesda assay.

公开(公告)号：EP3085783A1

公开(公告)日：2016-10-26

申请号：EP16162353.3

申请日：2004-10-08

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： HATTORI, Kunihiro ,  KOJIMA, Tetsuo ,  MIYAZAKI, Taro ,  SOEDA, Tetsuhiro

IPC分类号： C12N15/09 ,  C07K16/46 ,  A61K39/395 ,  A61P7/04

CPC分类号： C07K16/36 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622

摘要： The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulatioh factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.

摘要翻译： 本发明人成功构建了结合凝血因子IX /活化凝血因子IX和血液凝固因子X的双特异性抗体，功能上代替增强酶反应的凝血因子VIII /活化凝血因子VIII。

公开(公告)号：EP2902787A1

公开(公告)日：2015-08-05

申请号：EP13842222.5

申请日：2013-09-26

申请人： Chugai Seiyaku Kabushiki Kaisha ,  Public University Corporation Nara Medical University

发明人： SOEDA, Tetsuhiro ,  KITAZAWA, Takehisa ,  SHIMA, Midori

IPC分类号： G01N33/86

CPC分类号： C12Q1/56 ,  C12N9/6443 ,  G01N33/86 ,  G01N2333/755 ,  G01N2333/96452 ,  G01N2800/224

摘要： Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.

摘要翻译： 研究了各种评价止血效果的方法和各种血液凝固引发剂，构建了用具有代替凝血因子VIII（FVIII）的物质介导的血液凝固反应的评价方法。 结果发现，通过使用含有活化凝血因子XI（FXIa）和磷脂的凝血引发剂，可以使用具有代替凝血因子VIII（FVIII）的活性的物质对血液凝固反应的作用，使用 在血液样本中产生的凝血酶量作为指标。

公开(公告)号：EP3287791A1

公开(公告)日：2018-02-28

申请号：EP16782966.2

申请日：2016-03-30

申请人： Public University Corporation Nara Medical University ,  Chugai Seiyaku Kabushiki Kaisha ,  Sysmex Corporation

发明人： SHIMA, Midori ,  NOGAMI, Keiji ,  MATSUMOTO, Tomoko ,  KITAZAWA, Takehisa ,  SOEDA, Tetsuhiro ,  IKEDA, Yuka

IPC分类号： G01N33/86 ,  C12Q1/56 ,  G01N21/47 ,  G01N21/59

CPC分类号： G01N33/4905 ,  B01L3/00 ,  C12Q1/56 ,  G01N21/51 ,  G01N21/59 ,  G01N33/86 ,  G01N2201/122

摘要： The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention relates to an apparatus and computer program for evaluating coagulability of a blood specimen.

摘要翻译： 本发明涉及一种用于评估从施用具有凝固因子VIII取代活性的物质的对象获得的血液样本的凝固性的方法。 本发明还涉及用于凝血分析的试剂，用于凝血分析的试剂盒以及用于凝血分析的设备。 此外，本发明涉及用于评估血液样本的凝固性的装置和计算机程序。

公开(公告)号：EP2644698B1

公开(公告)日：2018-01-03

申请号：EP11842145.2

申请日：2011-11-17

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： IGAWA, Tomoyuki ,  SAMPEI, Zenjiro ,  KOJIMA, Tetsuo ,  SOEDA, Tetsuhiro ,  MUTO, Atsushi ,  KITAZAWA, Takehisa ,  NISHIDA, Yukiko ,  IMAI, Chifumi ,  SUZUKI, Tsukasa ,  YOSHIHASHI, Kazutaka

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61P7/04 ,  C07K16/36 ,  C12N5/10 ,  C12P21/02

CPC分类号： C07K16/40 ,  C07K16/36 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/94

摘要： Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.